ViewRay, Inc. (NASDAQ:VRAY) saw a large increase in short interest in May. As of May 31st, there was short interest totalling 3,886,151 shares, an increase of 39.1% from the May 15th total of 2,793,370 shares. Based on an average trading volume of 812,499 shares, the days-to-cover ratio is currently 4.8 days. Currently, 11.8% of the company’s stock are short sold.

Several equities research analysts have recently issued reports on VRAY shares. BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of ViewRay in a report on Wednesday, May 17th. Northland Securities reiterated a “buy” rating and set a $7.00 price target on shares of ViewRay in a report on Tuesday, May 16th. Aegis reiterated a “buy” rating and set a $11.00 price target on shares of ViewRay in a report on Tuesday, May 16th. Finally, ValuEngine upgraded ViewRay from a “sell” rating to a “hold” rating in a report on Friday, June 2nd.

Shares of ViewRay (NASDAQ:VRAY) opened at 6.17 on Tuesday. ViewRay has a one year low of $2.64 and a one year high of $10.39. The stock’s 50 day moving average price is $6.49 and its 200 day moving average price is $5.54. The firm’s market capitalization is $354.05 million.

ViewRay (NASDAQ:VRAY) last posted its quarterly earnings results on Monday, May 15th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.02. The company had revenue of $1.23 million during the quarter, compared to analyst estimates of $0.52 million. During the same quarter in the prior year, the business posted ($0.35) earnings per share. The business’s revenue for the quarter was down 77.5% compared to the same quarter last year. Analysts expect that ViewRay will post ($0.97) EPS for the current fiscal year.

In other ViewRay news, insider Fmr Llc sold 28,661 shares of ViewRay stock in a transaction dated Thursday, March 30th. The stock was sold at an average price of $8.46, for a total transaction of $242,472.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 1,385,274 shares of company stock worth $10,463,829. Company insiders own 59.10% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. UBS Group AG increased its position in ViewRay by 447.7% in the first quarter. UBS Group AG now owns 22,479 shares of the company’s stock worth $192,000 after buying an additional 18,375 shares during the period. Next Century Growth Investors LLC purchased a new position in ViewRay during the first quarter worth $2,987,000. Geode Capital Management LLC increased its position in ViewRay by 158.7% in the first quarter. Geode Capital Management LLC now owns 149,463 shares of the company’s stock worth $1,271,000 after buying an additional 91,694 shares during the period. Vanguard Group Inc. increased its position in ViewRay by 45.8% in the first quarter. Vanguard Group Inc. now owns 615,014 shares of the company’s stock worth $5,234,000 after buying an additional 193,138 shares during the period. Finally, Boston Financial Mangement LLC purchased a new position in ViewRay during the first quarter worth $170,000. 49.29% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/06/13/short-interest-in-viewray-inc-vray-rises-by-39-1.html.

ViewRay Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with MarketBeat.com's FREE daily email newsletter.